Meet the management of Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the design and development of drug candidates that play on the interaction between neurons and glial cells.
Built on a unique and patented technology, the Theranexus platform enables the generation of drug candidates with reduced development time and significantly increased market access opportunities. Its most advanced product is already in Phase 2, and is set to become the gold standard treatment for narcolepsy and excessive sleepiness in Parkinson’s disease
Tuesday, April 10th, 2018
BEDFORD Hotel 17, rue de l’Arcade – 75008 Paris
6:45 p.m. OPENING
7 p.m. THERANEXUS CONFERENCE
Franck MOUTHON, Chief Excecutive Officer
Mathieu CHARVERIAT, Scientific Director and Deputy Chief Executive Officer
Julien VEYS, Business Development Director
Thierry LAMBERT, Administrative and Financial Director
– In the front line against neurological diseases
– A disruptive approach to the central nervous system
– A capacity to generate drug candidates: already three developments in progress, a blockbuster potential
– An agile organization for controlled financial needs
– A creation of value in the short and medium term
– Discussions
8.30 p.m. Cocktail, discussions with management and networking
